mateon.comOncotelic – Welcome to Oncotelic

COVID-19 PipelineInvestors Corporate Videos Investor Overview Press Releases Stock Quote SEC Filings Events & Presentations Investor Contacts Email Alerts Corporate Governance Contact SearchWelcome! Acute and Long COVID-19 Learn more Pipeline Review our self immunization protocol against cancers through our pipeline. Learn More Pet2DAO Pet2DAO is using the power of corporate governance combined with DAO technology to revolutionize animal health Learn more Previous Next 1 2 3 Investor Relations Press, quotes, SEC filings, alerts, more. View Now COVID-19 OT-101 for COVID-19 Learn More Pipeline Cancer and viral infection treatment information. Details Pet2DAO Building the next generation DAO Overview YouTube Oncotelic YouTube Twitter Oncotelic Twitter LinkedIn Oncotelic Linkedin Facebook Oncotelic Facebook Discord Oncotelic Discord Reddit Oncotelic Reddit Most recent news and events Oncotelic Happenings Dr. Vuong Trieu presented at the BIO International Convention 2023, Boston, MA (June 5-8, 2023) Learn moreDr. Vuong Trieu presented at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research— Translating Knowledge into Practice (December 10 – 14, 2022, Maui, Hawaii) Learn moreDr. Cynthia Lee etc. presented at the SNO 2022 conference (November 16-20, 2022 | Tampa bay, FL) Learn more 1 Learn more 2 Dr. Anthony Maida presented at the SITC 2022 conference (November 8-12, 2022 | Boston, MA) Learn moreDr. Vuong Trieu presented at the 7th JCA-AACR Special Joint Conference (July 8-10, 2022) Learn moreDr. Vuong Trieu presented at the BIO International Convention, San Diego (June 13-16, 2022) Learn moreAACR Annual Meeting 2022. April 8 – 13, 2022, New Orleans, Louisiana. Learn moreDr. Vuong Trieu presented at the MedInvest Pharmaceutical & Biotechnology Investor Conference (March 30-31, 2022) Learn moreBiotechgate Digital Partnering February 2022 (7 – 11 Feb, 2022) Learn more2 nd Annual TGF-β for Immuno-Oncology Drug Development Summit ( tgf-beta-summit.com ) (January 25, 2022 to January 27, 2022) Learn moreOncotelic Therapeutics Investor Presentation 10-26-2021. Learn more11 Billion $ target markets 100 Plus patent applications 2 Key clinical programs 30 Years experience Questions or Comments? Contact us About Oncotelic Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). IMPORTANT LINKS COVID-19 Pipeline Investors Management Team Contact Us Our Office Oncotelic Corporate Headquarters 29397 Agoura Road, Suite 107 Agoura Hills, CA 91301 (650) 635 7000 (main) (650) 635 7001 (fax) ir@oncotelic.com Copyright © 2020 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved. Scroll to...